文献速递白血病

Quizartinib联合低剂量阿糖胞苷对比单用低剂量阿糖胞苷在老年急性髓系白血病患者中的随机评估

Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients.
PubMed 文献 · Blood Adv · 2021-01-01

本研究在不符合强化化疗条件的老年急性髓系白血病患者中,随机评估低剂量阿糖胞苷联合或不联合Quizartinib的疗效。这是首个在标准非强化化疗基础上加用FLT3靶向治疗并改善该人群生存的报告。

要点

  • 在FLT3-ITD阳性老年AML患者中,Quizartinib联合低剂量阿糖胞苷较单用低剂量阿糖胞苷显著改善2年总生存(HR 0.36)。
  • 总体202例患者中联合治疗未改善总生存,提示获益限于FLT3-ITD阳性亚组。

核心结论

  • 在不符合强化化疗的老年AML患者中,Quizartinib联合低剂量阿糖胞苷总体未改善生存,但FLT3-ITD阳性患者从联合治疗中显著获益。

研究设计与样本

  • 作为AML LI试验的一部分,开展随机评估低剂量阿糖胞苷联合或不联合Quizartinib,纳入不适合强化化疗的患者,总体202例,其中FLT3-ITD阳性27例。

主要发现

  • 总体202例患者中,联合Quizartinib未改善总生存。
  • FLT3-ITD阳性患者中,联合组中位总生存为13.7个月,单用组为4.2个月。

关键数值与推荐

  • FLT3-ITD阳性患者联合组中位总生存为13.7个月,单用组为4.2个月。

临床怎么用

  • 对于不适合强化化疗的FLT3-ITD阳性老年AML患者,可考虑在低剂量阿糖胞苷基础上加用Quizartinib。
  • 总体不适合强化化疗的老年AML患者中,Quizartinib联合低剂量阿糖胞苷未显示总体生存获益,需依据FLT3-ITD状态选择。

局限性

  • FLT3-ITD阳性亚组样本量小(共27例),结果需进一步验证。
  • 总体人群未观察到生存改善,获益仅限于FLT3-ITD阳性亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Survival for older patients with acute myeloid leukemia (AML) unsuitable for intensive chemotherapy is unsatisfactory. Standard nonintensive therapies have low response rates and only extend life by a few months. Quizartinib is an oral Fms-like tyrosine kinase 3 (FLT3) inhibitor with reported activity in wild-type patients. As part of the AML LI trial, we undertook a randomized evaluation of low-dose ara-C (LDAC) with or without quizartinib in patients not fit for intensive chemotherapy. Overall, survival was not improved (202 patients), but in the 27 FLT3-ITD patients, the addition of quizartinib to LDAC improved response (P = .05) with complete remission/complete remission with incomplete haematological recovery for quizartinib + LDAC in 5/13 (38%) vs 0/14 (0%) in patients receiving LDAC alone. Overall survival (OS) in these FLT3-ITD+ patients was also significantly improved at 2 years for quizartinib + LDAC (hazard ratio 0.36; 95% confidence intervals: 0.16, 0.85, P = .04). Median OS was 13.7 months compared with 4.2 months with LDAC alone. This is the first report of an FLT3-targeted therapy added to standard nonintensive chemotherapy that has improved survival in this population. Quizartinib merits consideration for future triplet-based treatment approaches. This trial was registered at www.clinicaltrials.gov as ISRCTN #ISRCTN40571019 and EUDRACT @2011-000749-19.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Dennis M, Thomas IF, Ariti C, et al. Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. Blood Adv. 2021. PMID: 34597366. doi:10.1182/bloodadvances.2021005038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。